Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E L Simpson

Showing results (51-60 of 100) with videos related to

Pageof 10
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|October 7, 2019
The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and CanadaM de Bruin-Weller, A Gadkari, S Auziere, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2020
Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trialsL A Beck, J I Silverberg, E L Simpson, et al.
The British Journal of Dermatology|February 6, 2019
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trialsA Blauvelt, D Rosmarin, T Bieber, et al.
Archives of Dermatological Research|July 11, 2023
Implementation of the HOME core outcome set for clinical trials of atopic eczema-barriers and opportunities: the HOME IX meeting reportM E Jacobson, K S Thomas, C J Apfelbacher, et al.
The Journal of Dermatological Treatment|November 23, 2020
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trialsK Reich, A M DeLozier, F P Nunes, et al.
The British Journal of Dermatology|May 11, 2018
Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) InitiativeE E Grinich, J Schmitt, D Küster, et al.
The British Journal of Dermatology|June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitisA Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|March 1, 2017
Altered composition of epidermal lipids correlates with Staphylococcus aureus colonization status in atopic dermatitisS Li, M Villarreal, S Stewart, et al.
The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.
Pageof 10

Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Journal of the European Academy of Dermatology and Venereology : JEADV|October 7, 2019
The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and CanadaM de Bruin-Weller, A Gadkari, S Auziere, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2020
Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trialsL A Beck, J I Silverberg, E L Simpson, et al.
The British Journal of Dermatology|February 6, 2019
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trialsA Blauvelt, D Rosmarin, T Bieber, et al.
Archives of Dermatological Research|July 11, 2023
Implementation of the HOME core outcome set for clinical trials of atopic eczema-barriers and opportunities: the HOME IX meeting reportM E Jacobson, K S Thomas, C J Apfelbacher, et al.
The Journal of Dermatological Treatment|November 23, 2020
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trialsK Reich, A M DeLozier, F P Nunes, et al.
The British Journal of Dermatology|May 11, 2018
Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) InitiativeE E Grinich, J Schmitt, D Küster, et al.
The British Journal of Dermatology|June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitisA Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|March 1, 2017
Altered composition of epidermal lipids correlates with Staphylococcus aureus colonization status in atopic dermatitisS Li, M Villarreal, S Stewart, et al.
The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.
Pageof 10